Table 1 Tissue-specific differentiation antigens
From: Tumor Antigens Discovery: Perspectives for Cancer Therapy
Antigens | HLA restrictions | Peptides | Comments |
|---|---|---|---|
Tyrosinase | HLA-A2 | MLLAVLYCL | Â |
HLA-A2 | YMNGTMSQV | ||
HLA-B44 | SEIWRDIDF | ||
HLA-A24 | AFLPWHRLF | ||
HLA-DR4 | QNILLSNAPLGPQFP | ||
HLA-DR4 | SYLQDSDPDSFQD | ||
MART-1/Melan-A gP100 | HLA-A2 | AAGIGILTV | |
HLA-A2 | KTWGQYWQV | ||
HLA-A2 | ITDQVPFSV | ||
HLA-A2 | YLEPGPVTA | ||
HLA-A2 | LLDGTATLRL | ||
HLA-A2 | VLYRYGSFSV | ||
HLA-A3 | ALLAVGATK | ||
HLA-A2 | VYFFLPDHL | Epitope generated from an intron of an incomplete splicing RNA | |
gP75/TRP-1 | HLA-A31 | MSLQRQFLR | Epitope was derived from an alternative ORF |
TRP-2 | HLA-A31 | LLGPGRPYR | Mouse TRP-2 was identified as a tumor antigen for B16 melanoma |